Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients

References

• Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054–1059
   PubMed Web of Science ®Google Scholar
• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122–2128
   PubMed Web of Science ®Google Scholar
• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: Past, present, and future. J Clin Invest 2006; 116: 2843–2854
   PubMed Web of Science ®Google Scholar
• Soliven BC, Lange DJ, Penn AS, Younger D, Jaretzki A, Lovelace 3rd RE, Rowland LP. Seronegative myasthenia gravis. Neurology 1988; 38: 514–517
   PubMed Web of Science ®Google Scholar
• Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: Clinical features, antibodies, and their targets. Lancet Neurol 2003; 2: 99–106
   PubMed Web of Science ®Google Scholar
• Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365–368
   PubMed Web of Science ®Google Scholar
• Skeie GO, Lunde PK, Sejersted OM, Mygland A, Aarli JA, Gilhus NE. Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta Physiol Scand 2001; 171: 379–384
   PubMedGoogle Scholar
• Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, Bourquin C, Bach JF, Garchon HJ. Anti-titin antibodies in myasthenia gravis: Tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001; 58: 885–890
   PubMed Web of Science ®Google Scholar
• Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005; 57: 289–293
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Nemoto Y, Misawa S, Takahashi H, Kawaguchi N, Hattori T. Anti-MuSK-positive myasthenia gravis: Neuromuscular transmission failure in facial and limb muscles. Acta Neurol Scand 2007; 115: 126–128
   PubMedGoogle Scholar
• Xu K, Jha S, Hoch W, Dryer S. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 2006; 143: 655–659
   PubMedGoogle Scholar
• Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004; 62: 2131–2132
   PubMedGoogle Scholar
• Ren HM, Zhou ZG, Chen XJ, Huang J, Lu CZ. Analysis of protein components of skeletal muscle from the patients with myasthenia gravis. Chin J Neurol 2000; 33: 227–230
   Google Scholar
• Ren HM, Zhou ZG, Chen XJ, Huang J, Lu CZ. Comparison of protein components in normal and myasthenia gravis skeletal muscles. Chin J Clin Neurosci 2000; 8: 260–262
   Google Scholar
• Ren HM, Lu CZ, Zhou ZG, Chen XJ, Huang J. Analysis of 25 kD protein content of skeletal muscles from the patients with myasthenia gravis. Chin J Neurol 2002; 35: 32–35
   Google Scholar
• Marvin LF, Roberts MA, Fay LB. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin Chim Acta 2003; 337: 11–21
   PubMed Web of Science ®Google Scholar
• Robert-Pachot M, Desbos A, Moreira A, Becchi M, Tebib J, Bonnin M, Aitsiselmi T, Bienvenu J, Fabien N. Carbonic anhydrase III: A new target for autoantibodies in autoimmune diseases. Autoimmunity 2007; 40: 380–389
   PubMed Web of Science ®Google Scholar
• Robert-Pachot M, Desbos A, Moreira A, Becchi M, Tebib J, Bonnin M, Aitsiselmi T, Bienvenu J, Fabien N. A new target for autoantibodies in patients with rheumatoid arthritis. Ann NY Acad Sci 2007; 1108: 382–391
   PubMedGoogle Scholar
• Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: Recommendations for clinical research standards. Neurology 2000; 55: 16–23
   PubMed Web of Science ®Google Scholar
• Fernandez-Patron C, Hardy E, Sosa A, Seoane J, Castellanos L. Double staining of Coomassie blue-stained polyacrylamide gels by immidazole–sodium dodecylsulfate–zinc reverse staining: Sensitive detection of Coomassie blue-undetected proteins. Anal Biochem 1995; 224: 263–269
   PubMedGoogle Scholar
• Spector T. Refinement of Coomassie blue method of protein quantitation: A simple and linear spectrophotometric assay for less than or equal to 0.5 to 50 microgram of protein. Anal Biochem 1978; 86: 142–146
   PubMed Web of Science ®Google Scholar
• Debus E, Weber K, Osborn M. Monoclonal antibodies to desmin, the muscle specific intermediate filament protein. EMBO J 1983; 2: 2305–2312
   PubMed Web of Science ®Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350–4354
   PubMed Web of Science ®Google Scholar
• Funatsu T, Higuchi H, Ishiwata S. Elastic filaments in skeletal muscle revealed by selective removal of titin filaments with plasma gelsolin. J Cell Biol 1990; 110: 53–62
   PubMed Web of Science ®Google Scholar
• Brooke MH, Kaiser KK. Muscle fiber types: How many and what kind?. Arch Neurol 1970; 23: 369–379
   PubMed Web of Science ®Google Scholar
• Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2: 797–804
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Schelton D, Fujii Y. Myasthenia gravis. Adv Immunol 1988; 42: 233–284
   PubMed Web of Science ®Google Scholar
• Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797–1810
   PubMed Web of Science ®Google Scholar
• Vaananen HK, Paloniemi M, Vuori J. Purification and localization of human carbonic anhydrase III. Typing of skeletal muscle fibres in paraffin embedded section. Histochemistry 1985; 83: 231–235
   PubMedGoogle Scholar
• Cabiscol E, Levine RL. Carbonic anhydrase III. J Biol Chem 1995; 270: 14742–14747
   PubMed Web of Science ®Google Scholar
• Carter N, Jeffery S, Shiels A, Edwards Y, Tipler T, Hopkinson DA. Characterization of human carbonic anhydrase III from skeletal muscle. Biochem Genet 1979; 17: 837–854
   PubMed Web of Science ®Google Scholar
• Lioyd J, McMillan S, Hopkinson D, Edwards YH. Nucleotide sequence and derived amino acid sequence of a cDNA encoding human muscle carbonic anhydrase. Gene 1986; 41: 233–239
   PubMedGoogle Scholar
• Gros G, Dodgson SJ. Velocity of CO2 exchange in muscle and liver. Ann Rev Physiol 1988; 50: 669–694
   PubMedGoogle Scholar
• Cote CH, Perreault G, Frenette J. Carbohydrate utilization in rat soleus muscle is influenced by carbonic anhydrase III activity. Am J Physiol Regul Integr Comp Physiol R 1997; 273: 1211–1218
   Google Scholar
• Geers C, Benz K, Gros G. Effects of carbonic anhydrase inhibitors on oxygen consumption and lactate accumulation in skeletal muscle. Comp Biochem Physiol A: Physiol 1995; 112: 111–117
   PubMedGoogle Scholar
• Geers C, Gros G. Effects of carbonic anhydrase inhibitors on contraction, intracellular pH and energy-rich phosphates of rat skeletal muscle. J Physiol 1990; 423: 279–297
   PubMed Web of Science ®Google Scholar
• Zimmerman U-J, Wang PW, Zhang X, Bogdanovich S, Forster R. Anti-oxidative response of carbonic anhydrase III in skeletal muscle. IUBMB Life 2004; 56: 343–347
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Jinno-Yoshida Y, Hamasaki Y, Ueki H. A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjogren's syndrome. J Dermotol Sci 1991; 2: 147–154
   PubMedGoogle Scholar
• Sly WS, Hewett-Emmett D, Whyte MP, Yu YSL, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 1983; 80: 2752–2756
   PubMed Web of Science ®Google Scholar
• Gailly P, Jouret F, Martin D, Debaix H, Parreira KS, Nishita T, Blanchard A, Antignac C, Willnow TE, Courtoy PJ, Scheinman SJ, Christensen EI, Devuyst O. A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction. Kidney Int 2008; 74: 52–61
   PubMedGoogle Scholar
• Carmignani M, Scoppetta C, Ranelletti F. Adverse interaction between acetazolamide and anticholinesterase drugs at the normal and myasthenic neuromuscular junction level. Int J Clin Pharmacol Ther Toxicol 1984; 22: 140–144
   PubMed Web of Science ®Google Scholar